Brief: Antengene Gets NMPA's Approval For Open-Label Phase Ib Dose-Escalation Study Of ATG-008 (Onatasertib) In Combination With ATG-010 (Selinexor)
02/11/2021 01:48
Nov 2 (Reuters) - Antengene Corporation Ltd 6996.HK :
* CHINA'S NMPA APPROVED OPEN-LABEL PHASE IB DOSE-ESCALATION
STUDY
OF ATG-008 (ONATASERTIB) IN COMBINATION WITH ATG-010 (SELINEXOR)
Source text for Eikon: ID:nHKS7VtP5H
Further company coverage: 6996.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Antengene
See all newsBiotech firm Antengene's H1 revenue jumps on licensing deals
Brief: Antengene Corp Expects HY Profit Of RMB195 MLN-RMB238 MLN
Brief: Antengene Corp Receives Initial $60 Million Upfront Payment From UCB
Brief: Antengene Corp Intends To Repurchase Up To 67.92 Million Shares
Brief: Antengene Corp Enters Exclusive License Agreement With K2 Therapeutics For Atg-106